ClinCalc Academy is excited to announce the launch of our newest online, video-based course — Biostatistics Rx. This course is designed specifically for busy healthcare professionals who want to transform their understanding of biostatistics and literature evaluation.
ClinCalc has released this year’s update to the DrugStats database — “The Top 200 Drugs of 2019”. DrugStats provides free access to prescription drug utilization data estimates for the United States. Using this data set, users can identify trends in prescribing practice and an official, reputable “top 200 drugs” list based on data provided by the U.S. Government.
All medication utilization data comes from the annual Medical Expenditure Panel Survey (MEPS), a survey conducted by the Agency for Healthcare Research and Quality (AHRQ) via the United States government. This data is publicly available on the MEPS website for free. In order for the ClinCalc DrugStats database to implement the MEPS data, basic data sanitization and standardization measures are necessary to maintain an accurate and reliable data set. Read more about the data set by clicking here. Continue reading
ClinCalc is proud to announce a new iOS app — RxHero, an educational game for healthcare students and professional to learn the Top 250 Drugs.
By default, Microsoft Word and other Office products do not contain brand and generic medication names within the spelling dictionary. For healthcare providers who conduct medical writing, publications, or PowerPoint lectures, this can lead to embarrassing spelling errors that are not captured by the spell check.
We’re proud to announce the annual update of the DrugStats database. DrugStats provides free access to prescription drug utilization data estimates for the United States. Using this data set, users can identify trends in prescribing practice and an official, reputable “top 200 drugs” list based on data provided by the U.S. Government.
All medication utilization data comes from the annual Medical Expenditure Panel Survey (MEPS), a survey conducted by the Agency for Healthcare Research and Quality (AHRQ) via the United States government. This data is publicly available on the MEPS website for free. In order for the ClinCalc DrugStats database to implement the MEPS data, basic data sanitization and standardization measures are necessary to maintain an accurate and reliable data set. Read more about the data set by clicking here.
Continue reading
We’re excited to announce the launch of our newest product at ClinCalc.com — the DrugStats Database! This database provides free, web-based access to outpatient prescription utilization statistics for the United States encompassing more than 3 billion prescriptions annually.
By leveraging the database, users can identify trends and compare usage of approximately 500 different outpatient medications. A few examples include: Continue reading
When evaluating a clinical trial, readers often jump to the P value of the primary endpoint to determine whether the results of a trial are “statistically significant” or not. Although the P value is truly a continuous variable, the scientific community has been conditioned to disregard all results with P values ≥ 0.05, but to fully endorse any trials with a “statistically significant” P value less than 0.05.
Putting the debate and controversy about P values aside for the moment, as a reader, would you be less impressed with a study that changed from being statistically significant to insignificant if one single patient changed from not having the primary endpoint to having the primary endpoint? Especially in an era with a blind reliance on P values, the knowledge of the “fragility” or “robustness” of a study’s P value is another useful data point for readers to critically understand and analyze the results of a clinical trial.
Colistin (in the form of colistimethate sodium, or CMS, in the United States) is an older, last-line agent for multidrug-resistant gram-negative infections. Because of colistin’s complex pharmacokinetics and for historical reasons, there is a paucity of data regarding its dosing in patients with severe gram negative infections, particularly for those with concurrent renal dysfunction.
In one of the largest pharmacokinetic analyses of colistin to date, Garonzik et al. published a detailed analysis of CMS dosing in critically ill patients. This analysis included dosing recommendations for patients with normal renal function, acutely changing renal function, intermittent hemodialysis (IHD), and continuous renal replacement therapy (CRRT).
ClinCalc is excited to announce our new colistin dosing calculator, which is based on the Garonzik pharmacokinetic recommendations. This calculator was developed in coordination with Julie Ann Justo, PharmD, MS, BCPS, AAHIVP — an Assistant Professor at the South Carolina College of Pharmacy who specializes in infectious diseases and HIV pharmacotherapy. Continue reading
We’re releasing a major update to the calculation for our popular vancomycin calculator today. Briefly, the new update implements more advanced calculations when adjusting a vancomycin dose based on a trough level.
When adjusting vancomycin based on a trough level, pharmacokinetic textbooks recommend estimating a vancomycin peak level using the following equation: Continue reading
ClinCalc.com is proud to announce that ICU Trials by ClinCalc, a mobile application that summarizes landmark critical care trials, has surpassed 100 studies in the app database!
With our most recent update on April 18th, the following recent and historic landmark trials were added: